N. Saba, K. Harrington, L. Licitra, J. Machiels, M. Huang, F. Xu, P. Patel, R. Haddad
{"title":"PD-L1阳性转移性头颈部鳞状细胞癌患者Zanzalintinib联合Pembrolizumab与Pembrolizumab单药治疗(STELLAR-305):一项双盲、随机、安慰剂对照的 2/3 期研究","authors":"N. Saba, K. Harrington, L. Licitra, J. Machiels, M. Huang, F. Xu, P. Patel, R. Haddad","doi":"10.1016/j.ijrobp.2024.01.092","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14219,"journal":{"name":"International Journal of Radiation Oncology*Biology*Physics","volume":"5 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study\",\"authors\":\"N. Saba, K. Harrington, L. Licitra, J. Machiels, M. Huang, F. Xu, P. Patel, R. Haddad\",\"doi\":\"10.1016/j.ijrobp.2024.01.092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14219,\"journal\":{\"name\":\"International Journal of Radiation Oncology*Biology*Physics\",\"volume\":\"5 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology*Biology*Physics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.01.092\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology*Biology*Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.01.092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study